Cancer Research Meeting Calendar Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Campbell, I. G.
Right arrow Articles by Phillips, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Campbell, I. G.
Right arrow Articles by Phillips, W. A.
[Cancer Research 64, 7678-7681, November 1, 2004]
© 2004 American Association for Cancer Research

Advances in Brief

Mutation of the PIK3CA Gene in Ovarian and Breast Cancer

Ian G. Campbell1, Sarah E. Russell1,2, David Y. H. Choong1, Karen G. Montgomery1, Marianne L. Ciavarella2, Christine S. F. Hooi1, Briony E. Cristiano3, Richard B. Pearson3 and Wayne A. Phillips2

1 VBCRC Cancer Genetics Laboratory, 2 Surgical Oncology Research Laboratory, and 3 Protein Chemistry Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 
Phosphatidylinositol 3'-kinases are lipid kinases with important roles in neoplasia. Recently, a very high frequency of somatic mutations in PIK3CA has been reported among a large series of colorectal cancers. However, the relevance of PIK3CA mutation in other cancer types remains unclear because of the limited number of tumors investigated. We have screened a total of 284 primary human tumors for mutations in all coding exons of PIK3CA using a combination of single stranded conformational polymorphism and denaturing high-performance liquid chromatography analysis. Among 70 primary breast cancers, 40% (28 of 70) harbored mutations in PIK3CA, making it the most common mutation described to date in this cancer type. Mutations were not associated with histologic subtype, estrogen receptor status, grade or presence of tumor in lymph nodes. Among the primary epithelial ovarian cancers only 11 of 167 (6.6%) contain somatic mutations, but there was a clear histologic subtype bias in their distribution. Only 2 of 88 (2.3%) of serous carcinomas had PIK3CA mutations compared with 8 of 40 (20.0%) endometrioid and clear cell cancers, which was highly significant (P = 0.001). In contrast, PIK3CA gene amplification (>7-fold) was common among all histologic subtypes (24.5%) and was inversely associated with the presence of mutations. Overall, PIK3CA mutation or gene amplification was detected in 30.5% of all ovarian cancers and 45% of the endometrioid and clear cell subtypes. Our study is the first direct evidence that PIK3CA is an oncogene in ovarian cancer and greatly extends recent findings in breast cancer.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results and Discussion
 REFERENCES
 
The class IA phosphatidylinositol 3'-kinases (PI3K) are a family of widely expressed lipid kinases that exist as heterodimers consisting of a unique catalytic subunit (p110{alpha}, ß, or {delta}) along with one of a number of shared regulatory subunits (p85{alpha}, p85ß, or p55{gamma}; ref. 1 ). Numerous genetic and functional studies have clearly established a fundamental role for the PI3K pathway in the development of neoplasia. As a tumor suppressor, the role of PTEN, a negative regulator of the PI3K pathway, has been well-documented whereas Akt, a major downstream target of PI3K, has been shown to be activated and/or overexpressed in a number of human cancers (2 , 3) . PI3K itself has also been shown to be dysregulated in human cancers. Amplification of the PIK3CA gene (which codes for the p110{alpha} catalytic subunit of PI3K) has been reported in a number of different tumor types (4 , 5) . However, we were the first to provide direct evidence for an oncogenic role for PI3K in human cancer by showing the presence of activating somatic mutations in the p85{alpha} regulatory subunit of PI3K (PIK3R1) in primary ovarian and colon tumors (6) . Although the mutation frequency was low, it raised the possibility that other members of the PI3K family might be activated by somatic mutations. This has been borne out by the recent report of a very high frequency of somatic mutations in PIK3CA among a large series of colorectal cancers (7) . However, the relevance of PIK3CA mutation in other cancer types remains unclear because few tumors of other types were investigated. In particular, no ovarian cancers and only 12 breast cancers were included in that study. Therefore, we undertook a search for somatic mutations in a large series of ovarian and breast cancers to establish the role that PIK3CA mutation plays in the etiology of these important malignancies.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results and Discussion
 REFERENCES
 
Tumor Samples.
Matching normal and tumor DNA from 70 primary breast cancers was provided by the Peter MacCallum Cancer Centre tissue bank or by Dr. Nick Hayward (Queensland Institute for Medical Research, Brisbane, Australia). One hundred and eighty-two primary ovarian tumor samples were obtained from hospitals in the south of England. DNA was extracted from fresh cancer tissue and matching peripheral blood samples were used as a source of normal DNA. Thirty-two colon carcinomas were obtained from patients undergoing elective surgery at Western Hospital (Victoria, Australia). Normal DNA was extracted from normal-appearing mucosa >5 cm from the margins of the carcinoma. The collection and use of tissues for this study were approved by the appropriate institutional ethics committees.

Screening for Mutations.
Exons 1–20 of PIK3CA were individually amplified from genomic DNA with primers complementary to surrounding intronic sequences. Details of these primers are available on request. PCR was carried out with 10 ng of genomic DNA in a reaction volume of 10 µL, with the inclusion of 0.5µCi of [{alpha}-32P]dATP and 0.1 units Hot Star TaqDNA polymerase (Qiagen, Valencia, CA). After an initial denaturation step of 95°C for 10 minutes, a "touch-down" program was used consisting of 2 cycles of amplification at annealing temperatures of 63°C to 59°C; followed by 30 amplification cycles at an annealing temperature of 58°C and a final extension cycle of 72°C for 5 minutes. Samples were prepared for single-strand conformational polymorphism (SSCP) analysis and separated on 0.5x mutation detection enhancement gel matrix (BioWhittaker Molecular Applications Inc., Rockland, ME) as described previously (8) .

In addition to SSCP analysis, exons 9 and 20 were screened for mutations by denaturing high performance liquid chromatography (DHPLC) with the Varian-Helix DHPLC system (Varian, Inc., Palo Alto, CA). To enhance heteroduplex formation, PCR products were subjected to an additional 95°C denaturation step for 5 minutes followed by gradual reannealing from 95°C to 60°C over a 40 minute period before analysis. PCR products were then introduced into the mobile phase in an injection volume of 3 µL. The products were eluted from the column with a 100 mmol/L triethylammonium acetate buffer (pH 7.0) containing 25% acetonitrile gradient at a flow rate of 0.45 mL/minutes. Temperatures required for the successful resolution of heteroduplex molecules were determined by the use of the DHPLC melting algorithm.4

Cases showing aberrant band shifts by SSCP or DHPLC were repeated and compared with the matching normal DNA (where available) to determine whether the change was germline or somatic. Tumors showing somatic changes or harboring rare germline variants were reamplified and sequenced directly with the BigDye terminator method (Applied Biosystems; Warrington, United Kingdom or Forster City, CA) on an autosequencer (ABI PRISM 3100).

Screening for Gene Amplification.
PIK3CA gene amplification was assessed by SYBR Green quantitative PCR with primers to genomic sequences (PIK3CA forward, 5'-TATGGTTGTCTGTCAATCGGTGA-3'; PIK3CA reverse, 5'-GCCTTTGCAGTGAATTTGCAT) and compared with the signal obtained from two control genes KRAS2 (KRAS forward, 5'-CTGAAGATGTACCTATGGTCCTAGTAGG-3'; KRAS reverse, 5'-AAGTCCTGAGCCTGTTTTGTGTC-3') and BARD1 (BARD1 forward, 5'-TTCTGTAGCCAACCATCTGTTATCTC-3'; BARD1 reverse, 5'-TCAGATTCTGTCAAGGAGCCACT-3'). KRAS2 and BARD1 were selected as controls based on a scan of the literature indicating that they are located in regions not frequently showing loss of heterozygosity or amplification in breast, ovarian, or colorectal cancers. PCR was carried out with SYBR Green PCR Master Mix (Applied Biosystems) on an ABI Prism 7000 sequence detection system. We analyzed all results on a standard curve derived from a known sample concentration and used on each assay. Cycle threshold values obtained were then compared with the standard curve, and nanogram values were used in the subsequent analysis. Three normal samples were also used on each assay, and the mean value of these was used to normalize the data and correct for inter-assay variation. The PIK3CA gene copy number was calculated by dividing its value by the mean of the KRAS2 and BARD1 values. High-level DNA amplification was arbitrarily and conservatively defined as values >7.


   Results and Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
REFERENCES
 
Two hundred and eighty-four primary breast, ovarian, and colorectal cancers were screened for mutations in all 20 exons of the PIK3CA gene. SSCP analysis was used as the primary means of mutation detection because it combines relatively high sensitivity with the ability to detect mutations even in the presence of a high background of normal DNA contamination. To further increase sensitivity, DHPLC was used to analyze exons 9 and 20, where the majority of mutations have thus far been reported (7) . All of the exon 9 and 20 mutations detected by DHPLC were also easily visualized on SSCP gels, examples of which are shown in Fig. 1Citation . Table 1Citation summarizes the 45 mutations that were identified among the primary cancers. Mutations were identified in exons 6, 7, 9, 14, and 20, with the vast majority (88.9%) occurring in exons 9 and 20. Matching normal DNA was available for all but eight tumors and in all instances the mutations were shown to be somatic. With the exception of the putative exon 14 A2198G (K733R) mutation, the alterations detected among the eight cases (three colorectal and five breast cancers) where no matching normal DNA was available have been shown to be somatic changes in primary cancers. A number of lines of evidence indicate that these represent pathologic mutations rather than benign chance somatic events. First, the frequency of somatic mutations far exceeds the expected background rate, and all 45 mutations were nonsynonymous changes. As expected for an oncogene, all of the mutations were either missense changes or in-frame deletions. Finally, in vitro studies have shown that the H1047R mutant, which is the most common mutation detected in our study, has increased lipid kinase activity (7) .



View larger version (41K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Somatic mutations found in the PIK3CA gene in ovarian and breast cancers. Aberrant band shifts were detected by both SSCP and DHPLC in the tumor DNA (T) compared with the matching normal DNA (N). The sequence trace of the tumor DNA is shown and the mutation indicated.

 

View this table:
[in this window]
[in a new window]

  		Table 1 PIK3CA mutations among primary ovarian, breast, and colorectal cancers

 
The frequency, location, and type of mutations detected among the colorectal cancers were consistent with those reported by Samuels et al. (7) . In addition, we found no evidence of gene amplification as assessed by quantitative real-time PCR, a result consistent with previous studies (7) . Among the 70 breast cancers, 28 (40.0%) harbored somatic mutations, with 53.6 and 32.1% occurring in exon 9 or 20, respectively. Interestingly, 4 of 9 exon 20 mutations detected in the breast cancers were of the H1047L type compared with only 1 of 22 reported by Samuels et al. (7) among 234 colon cancers. Nevertheless, the overall proportion of exon 9 and exon 20 mutations detected in the breast cancers is almost identical to that observed by Samuels et al. (54% and 31%, respectively) suggesting that there is no major difference in the selection advantage of these mutations between these two cancer types. Two mutations occurring in the breast cancers have not been reported previously; a 15 bp deletion of nucleotides 1352–1366 in exon 7 and a C1241T (S405P) substitution in exon 6. Only one invasive ductal breast tumor showed amplification (22-fold) of the PIK3CA gene. As summarized in Table 2Citation , there was no evidence of an association of mutations with histologic type, estrogen receptor status, tumor grade, or nodal status. A recent study by Bachman et al. (9) of a smaller set of 41 breast tumors identified somatic PIK3CA mutations in 22% of cases, which is significantly lower than the 40% reported here. The discrepancy is explained in part by the fact that Bachman et al. only analyzed the mutation hot spots (based on the spectrum of mutations found in colorectal cancers) in exons 1, 9, and 20. In addition, our adoption of an SSCP-based mutation analysis is likely to have improved the detection rate because, unlike direct DNA sequencing, the sensitivity of SSCP is maintained even in the presence of high normal DNA contamination. This is particularly critical when screening for oncogenic mutations where unmasking of a mutant allele through loss of heterozygosity of the wild-type allele rarely occurs.


View this table:
[in this window]
[in a new window]

  		Table 2 PIK3CA mutations and histologic subtype among breast cancers

 
With respect to the spectrum of mutations identified, Bachman et al. (9) suggested that exon 20 mutations predominate in breast cancers in contrast to colorectal cancers where exon 9 mutations are more common. Our data does not support this and highlights the need to be cautious when defining both tumor type-specific mutations and mutational hot spots at this early stage where relatively few primary tumors have been analyzed. In fact, the proportion of exon 9 to exon 20 mutations identified in our larger cohort of breast tumors (15 versus 9) is almost identical to the proportion identified by Samuels et al. (7) among colorectal cancers (43 versus 27). Furthermore, 14.3% of the mutations identified in our breast cancer cohort were outside the mutation "hot spots" identified by Bachman et al. (9) .

Mutations among the ovarian tumors were only identified in exons 9 and 20 (Table 1)Citation . Overall, only 6% of the tumors (6.6% of the malignant tumors) harbored PIK3CA mutations. However, stratifying the ovarian cancer according to histologic subtype reveals a striking bias in the distribution of the mutations. Only 2 of 88 (2.3%) of the serous and none of 24 mucinous carcinomas harbored somatic PIK3CA mutations compared with 8 of 40 (20%) of the endometrioid and clear cell ovarian cancers. This finding is consistent with the concept that the major histologic subtypes, serous, endometrioid, clear cell, and mucinous arise through different developmental pathways. In particular, we have shown that endometrioid and clear cell ovarian cancers probably arise through malignant transformation of endometriosis and not the ovarian surface epithelium (10 , 11) .

Chromosomal amplifications are commonly associated with activation of oncogenes, and therefore we assessed the PIK3CA copy number by real-time quantitative PCR. PIK3CA gene amplification was common among the ovarian cancers (24.6%) but absent in the borderline and benign tumors (Table 3)Citation . The mean copy number increase was 35-fold with highest amplification of 226-fold recorded in an endometrioid cancer. In contrast to the distribution of somatic PIK3CA mutation, gene amplification was not restricted to any particular histologic subtype with the serous ovarian cancers showing a similar frequency to the endometrioid and clear cell cancers. Interestingly, there was an almost perfect reciprocal association of the presence of gene amplification and a somatic PIK3CA mutation suggesting that these only occur in tumors without amplification. Furthermore, in previous studies we did mutational analysis on a subset of these ovarian cancers for both p85{alpha} (PIK3R1), which is a regulatory binding partner to p110{alpha} and PTEN (6 , 12) . Among 66 cancers, we identified one mucinous tumor with a somatic p85{alpha} mutation and three endometrioid tumors with somatic PTEN mutations. None of the four cancers harbored a PIK3CA mutation and none showed gene amplification.


View this table:
[in this window]
[in a new window]

  		Table 3 PIK3CA mutations and amplification among histologic subtypes of ovarian tumors

 
The data shows that somatic changes in PIK3CA through mutation or gene amplification is extremely common in ovarian cancer with 30.5% harboring one or the other alteration. Among the endometrioid and clear cell ovarian cancers, PIK3CA involvement is even more striking with 45% harboring one or other alteration. With respect to the gene amplification however, it should be noted that the 3q26 region harbors several putative oncogenes. Consequently, it is possible that the amplification we and others have observed in ovarian cancers (5) might not be targeting PIK3CA in all cases (13) . Although a strong case could be made for a direct association of gene amplification with involvement of PIK3CA among the endometrioid and clear cell cancers (because they show a concomitant high frequency of somatic mutations), the argument is not as strong for the other histologic subtypes. Indeed, it is curious why PIK3CA amplification should be so common among the serous ovarian cancers whereas somatic mutations are quite rare and why one serous tumor showed PIK3CA gene amplification (15-fold) despite the coexistence of a somatic coding mutation. Although Shayesteh et al. (5) has shown increased PIK3CA transcription and p110{alpha} protein expression in many (but not all) ovarian cancer cell lines with PIK3CA amplification, it will be important to verify specific targeting of the PIK3CA gene in ovarian cancers through detailed amplicon mapping studies.

In summary, our comprehensive mutation screen has unequivocally established that PIK3CA mutations occur with high frequency in both ovarian and breast tumors. These data, together with other studies demonstrating the involvement of other components of the PI3K pathway in these tumors, suggests that the PI3K pathway plays a central role in breast and ovarian tumorigenesis and implies that this pathway may be a valuable target for the development of novel therapies for these cancers.


   FOOTNOTES
 
Grant support: a grant from the National Health and Medical Research Council of Australia.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Ian Campbell, VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Locked Bag 1, A’Beckett Street, Melbourne, Victoria 8006, Australia. Phone: 61-3-96561803; Fax: 61-3-96561411; E-mail: ian.campbell{at}petermac.org

4 http://intersion.Standford.edu/melt.html. Back

Received 8/13/04. Revised 9/ 6/04. Accepted 9/10/04.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 

  1. Vanhaesebroeck B, Waterfield MD Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999;253:239-254.[CrossRef][Medline]
  2. Parsons R Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol 2004;15:171-176.[CrossRef][Medline]
  3. Vivanco I, Sawyers CL The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.[CrossRef][Medline]
  4. Ma YY, Wei SJ, Lin YC, et al PIK3CA as an oncogene in cervical cancer. Oncogene 2000;19:2739-2744.[CrossRef][Medline]
  5. Shayesteh L, Lu Y, Kuo WL, et al PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102.[CrossRef][Medline]
  6. Philp AJ, Campbell IG, Leet C, et al The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001;61:7426-7429.[Abstract/Free Full Text]
  7. Samuels Y, Wang Z, Bardelli A, et al High frequency of mutations of the PIK3CA gene in human cancers. Science (Wash D C) 2004;304:554
  8. Campbell IG, Nicolai HM, Foulkes WD, et al A novel gene encoding a B-Box protein within the BRCA1 region at 17q21.1. Hum Mol Genet 1994;3:589-594.[Abstract/Free Full Text]
  9. Bachman KE, Argani P, Samuels Y, et al The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004;3:49-52.
  10. Jiang X, Hitchcock A, Bryan EJ, et al Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Cancer Res 1996;56:3534-3539.[Abstract/Free Full Text]
  11. Jiang X, Morland SJ, Hitchcock A, Thomas E, Campbell IG Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res 1998;58:1707-1712.[Abstract/Free Full Text]
  12. Obata K, Morland SJ, Watson RH, et al Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998;58:2095-2097.[Abstract/Free Full Text]
  13. Guan XY, Sham JS, Tang TC, Fang Y, Huo KK, Yang JM Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. Cancer Res 2001;61:3806-3809.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Ann OncolHome page
B. Markman, F. Atzori, J. Perez-Garcia, J. Tabernero, and J. Baselga
Status of PI3K inhibition and biomarker development in cancer therapeutics
Ann. Onc., August 27, 2009; (2009) mdp347v1.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Kalinsky, L. M. Jacks, A. Heguy, S. Patil, M. Drobnjak, U. K. Bhanot, C. V. Hedvat, T. A. Traina, D. Solit, W. Gerald, et al.
PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
Clin. Cancer Res., August 15, 2009; 15(16): 5049 - 5059.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
Y. Kataoka, T. Mukohara, H. Shimada, N. Saijo, M. Hirai, and H. Minami
Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
Ann. Onc., July 24, 2009; (2009) mdp304v1.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K.-T. Kuo, T.-L. Mao, S. Jones, E. Veras, A. Ayhan, T.-L. Wang, R. Glas, D. Slamon, V. E. Velculescu, R. J. Kuman, et al.
Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma
Am. J. Pathol., May 1, 2009; 174(5): 1597 - 1601.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Wu, L. Jung, A. B. Cooper, C. Fleet, L. Chen, L. Breault, K. Clark, Z. Cai, S. Vincent, S. Bottega, et al.
Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice
PNAS, April 28, 2009; 106(17): 7022 - 7027.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Wang, A. Rajput, J. L. C. Kan, R. Rose, X.-Q. Liu, K. Kuropatwinski, J. Hauser, A. Beko, I. Dominquez, E. A. Sharratt, et al.
Knockdown of Ron Kinase Inhibits Mutant Phosphatidylinositol 3-Kinase and Reduces Metastasis in Human Colon Carcinoma
J. Biol. Chem., April 17, 2009; 284(16): 10912 - 10922.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
Y. Lin, X. Jiang, Y. Shen, M. Li, H. Ma, M. Xing, and Y. Lu
Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors
Endocr. Relat. Cancer, March 1, 2009; 16(1): 301 - 310.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
R. Sasaki, M. Narisawa-Saito, T. Yugawa, M. Fujita, H. Tashiro, H. Katabuchi, and T. Kiyono
Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes
Carcinogenesis, March 1, 2009; 30(3): 423 - 431.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
O. K. Mirzoeva, D. Das, L. M. Heiser, S. Bhattacharya, D. Siwak, R. Gendelman, N. Bayani, N. J. Wang, R. M. Neve, Y. Guan, et al.
Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
Cancer Res., January 15, 2009; 69(2): 565 - 572.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
O. Renner, C. Blanco-Aparicio, M. Grassow, M. Canamero, J. F.M. Leal, and A. Carnero
Activation of Phosphatidylinositol 3-Kinase by Membrane Localization of p110{alpha} Predisposes Mammary Glands to Neoplastic Transformation
Cancer Res., December 1, 2008; 68(23): 9643 - 9653.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. Serra, B. Markman, M. Scaltriti, P. J.A. Eichhorn, V. Valero, M. Guzman, M. L. Botero, E. Llonch, F. Atzori, S. Di Cosimo, et al.
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
Cancer Res., October 1, 2008; 68(19): 8022 - 8030.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Oda, J. Okada, L. Timmerman, P. Rodriguez-Viciana, D. Stokoe, K. Shoji, Y. Taketani, H. Kuramoto, Z. A. Knight, K. M. Shokat, et al.
PIK3CA Cooperates with Other Phosphatidylinositol 3'-Kinase Pathway Mutations to Effect Oncogenic Transformation
Cancer Res., October 1, 2008; 68(19): 8127 - 8136.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Wee, D. Wiederschain, S.-M. Maira, A. Loo, C. Miller, R. deBeaumont, F. Stegmeier, Y.-M. Yao, and C. Lengauer
PTEN-deficient cancers depend on PIK3CB
PNAS, September 2, 2008; 105(35): 13057 - 13062.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S.-H. Lo, H. Chernoff, L. Cong, Y. Ding, and T. Zheng
Discovering interactions among BRCA1 and other candidate genes associated with sporadic breast cancer
PNAS, August 26, 2008; 105(34): 12387 - 12392.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. B. Kaye
Reversal of Drug Resistance in Ovarian Cancer: Where Do We Go From Here?
J. Clin. Oncol., June 1, 2008; 26(16): 2616 - 2618.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. E. Board, N. J. Thelwell, P. F. Ravetto, S. Little, M. Ranson, C. Dive, A. Hughes, and D. Whitcombe
Multiplexed Assays for Detection of Mutations in PIK3CA
Clin. Chem., April 1, 2008; 54(4): 757 - 760.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. Zhao and P. K. Vogt
Helical domain and kinase domain mutations in p110{alpha} of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
PNAS, February 19, 2008; 105(7): 2652 - 2657.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
C.-H. Huang, D. Mandelker, O. Schmidt-Kittler, Y. Samuels, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, S. B. Gabelli, and L. M. Amzel
The Structure of a Human p110{alpha}/p85{alpha} Complex Elucidates the Effects of Oncogenic PI3K{alpha} Mutations
Science, December 14, 2007; 318(5857): 1744 - 1748.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Barbareschi, F. Buttitta, L. Felicioni, S. Cotrupi, F. Barassi, M. Del Grammastro, A. Ferro, P. Dalla Palma, E. Galligioni, and A. Marchetti
Different Prognostic Roles of Mutations in the Helical and Kinase Domains of the PIK3CA Gene in Breast Carcinomas
Clin. Cancer Res., October 15, 2007; 13(20): 6064 - 6069.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Zhang, J. Huang, N. Yang, J. Greshock, S. Liang, K. Hasegawa, A. Giannakakis, N. Poulos, A. O'Brien-Jenkins, D. Katsaros, et al.
Integrative Genomic Analysis of Phosphatidylinositol 3'-Kinase Family Identifies PIK3R3 as a Potential Therapeutic Target in Epithelial Ovarian Cancer
Clin. Cancer Res., September 15, 2007; 13(18): 5314 - 5321.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. L. Howes, G. G. Chiang, E. S. Lang, C. B. Ho, G. Powis, K. Vuori, and R. T. Abraham
The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures
Mol. Cancer Ther., September 1, 2007; 6(9): 2505 - 2514.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
C. Blanco-Aparicio, O. Renner, J. F.M. Leal, and A. Carnero
PTEN, more than the AKT pathway
Carcinogenesis, July 1, 2007; 28(7): 1379 - 1386.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
O. Renner, J. Fominaya, S. Alonso, C. Blanco-Aparicio, J. F.M. Leal, and A. Carnero
Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate
Carcinogenesis, July 1, 2007; 28(7): 1418 - 1425.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Perez-Tenorio, L. Alkhori, B. Olsson, M. A. Waltersson, B. Nordenskjold, L. E. Rutqvist, L. Skoog, and O. Stal
PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer
Clin. Cancer Res., June 15, 2007; 13(12): 3577 - 3584.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Nanjundan, Y. Nakayama, K. W. Cheng, J. Lahad, J. Liu, K. Lu, W.-L. Kuo, K. Smith-McCune, D. Fishman, J. W. Gray, et al.
Amplification of MDS1/EVI1 and EVI1, Located in the 3q26.2 Amplicon, Is Associated with Favorable Patient Prognosis in Ovarian Cancer
Cancer Res., April 1, 2007; 67(7): 3074 - 3084.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Gymnopoulos, M.-A. Elsliger, and P. K. Vogt
Rare cancer-specific mutations in PIK3CA show gain of function
PNAS, March 27, 2007; 104(13): 5569 - 5574.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Wang, K. Kuropatwinski, J. Hauser, M. R. Rossi, Y. Zhou, A. Conway, J. L.C. Kan, N. W. Gibson, J. K.V. Willson, J. K. Cowell, et al.
Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis
Mol. Cancer Ther., March 1, 2007; 6(3): 1143 - 1150.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Hou, D. Liu, Y. Shan, S. Hu, K. Studeman, S. Condouris, Y. Wang, A. Trink, A. K. El-Naggar, G. Tallini, et al.
Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer
Clin. Cancer Res., February 15, 2007; 13(4): 1161 - 1170.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Maruyama, Y. Miyoshi, T. Taguchi, Y. Tamaki, M. Monden, and S. Noguchi
Clinicopathologic Analysis of Breast Cancers with PIK3CA Mutations in Japanese Women
Clin. Cancer Res., January 15, 2007; 13(2): 408 - 414.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. E. Cristiano, J. C. Chan, K. M. Hannan, N. A. Lundie, N. J. Marmy-Conus, I. G. Campbell, W. A. Phillips, M. Robbie, R. D. Hannan, and R. B. Pearson
A Specific Role for AKT3 in the Genesis of Ovarian Cancer through Modulation of G2-M Phase Transition
Cancer Res., December 15, 2006; 66(24): 11718 - 11725.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. P. Hayes, H. Wang, R. Espinal-Witter, W. Douglas, G. J. Solomon, S. J. Baker, and L. H. Ellenson
PIK3CA and PTEN Mutations in Uterine Endometrioid Carcinoma and Complex Atypical Hyperplasia.
Clin. Cancer Res., October 15, 2006; 12(20): 5932 - 5935.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
G. L. Gallia, V. Rand, I-M. Siu, C. G. Eberhart, C. D. James, S. K.N. Marie, S. M. Oba-Shinjo, C. G. Carlotti, O. L. Caballero, A. J.G. Simpson, et al.
PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme
Mol. Cancer Res., October 1, 2006; 4(10): 709 - 714.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. W. Watters and C. J. Roberts
Developing gene expression signatures of pathway deregulation in tumors.
Mol. Cancer Ther., October 1, 2006; 5(10): 2444 - 2449.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
Y. C. Antill, G. Mitchell, S. A. Johnson, L. Devereux, A. Milner, K.-A. Phillips, and I. G. Campbell
Loss of Heterozygosity Analysis in Ductal Lavage Samples from BRCA1 and BRCA2 Carriers: A Cautionary Tale.
Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1396 - 1398.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
T. R. Pettitt, S. K. Dove, A. Lubben, S. D. J. Calaminus, and M. J. O. Wakelam
Analysis of intact phosphoinositides in biological samples
J. Lipid Res., July 1, 2006; 47(7): 1588 - 1596.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
N. Pore, Z. Jiang, H.-K. Shu, E. Bernhard, G. D. Kao, and A. Maity
Akt1 Activation Can Augment Hypoxia-Inducible Factor-1{alpha} Expression by Increasing Protein Translation through a Mammalian Target of Rapamycin-Independent Pathway
Mol. Cancer Res., July 1, 2006; 4(7): 471 - 479.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. G. Campbell, W. A. Phillips, and D. Y.H. Choong
Genetic and Epigenetic Analysis of the Putative Tumor Suppressor km23 in Primary Ovarian, Breast, and Colorectal Cancers.
Clin. Cancer Res., June 15, 2006; 12(12): 3713 - 3715.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Schonleben, W. Qiu, N. T. Ciau, D. J. Ho, X. Li, J. D. Allendorf, H. E. Remotti, and G. H. Su
PIK3CA Mutations in Intraductal Papillary Mucinous Neoplasm/Carcinoma of the Pancreas.
Clin. Cancer Res., June 15, 2006; 12(12): 3851 - 3855.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Yao, S. Weremowicz, B. Feng, R. C. Gentleman, J. R. Marks, R. Gelman, C. Brennan, and K. Polyak
Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression.
Cancer Res., April 15, 2006; 66(8): 4065 - 4078.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. L. Janmaat, M. I. Gallegos-Ruiz, J. A. Rodriguez, G. A. Meijer, W. L. Vervenne, D. J. Richel, C. Van Groeningen, and G. Giaccone
Predictive Factors for Outcome in a Phase II Study of Gefitinib in Second-Line Treatment of Advanced Esophageal Cancer Patients
J. Clin. Oncol., April 1, 2006; 24(10): 1612 - 1619.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Qiu, F. Schonleben, X. Li, D. J. Ho, L. G. Close, S. Manolidis, B. P. Bennett, and G. H. Su
PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., March 1, 2006; 12(5): 1441 - 1446.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
V. Jung, R. Kindich, J. Kamradt, M. Jung, M. Muller, W. A. Schulz, R. Engers, G. Unteregger, M. Stockle, R. Zimmermann, et al.
Genomic and Expression Analysis of the 3q25-q26 Amplification Unit Reveals TLOC1/SEC62 as a Probable Target Gene in Prostate Cancer
Mol. Cancer Res., March 1, 2006; 4(3): 169 - 176.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
F. Moll, C. Millet, D. Noel, B. Orsetti, A. Bardin, D. Katsaros, C. Jorgensen, M. Garcia, C. Theillet, P. Pujol, et al.
Chordin is underexpressed in ovarian tumors and reduces tumor cell motility
FASEB J, February 1, 2006; 20(2): 240 - 250.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Moscova, D. J. Marsh, and R. C. Baxter
Protein Chip Discovery of Secreted Proteins Regulated by the Phosphatidylinositol 3-Kinase Pathway in Ovarian Cancer Cell Lines
Cancer Res., February 1, 2006; 66(3): 1376 - 1383.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. A. Granville, R. M. Memmott, J. J. Gills, and P. A. Dennis
Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway
Clin. Cancer Res., February 1, 2006; 12(3): 679 - 689.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H.-J. Kim, X. Cui, S. G. Hilsenbeck, and A. V. Lee
Progesterone Receptor Loss Correlates with Human Epidermal Growth Factor Receptor 2 Overexpression in Estrogen Receptor-Positive Breast Cancer
Clin. Cancer Res., February 1, 2006; 12(3): 1013s - 1018s.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. G. Bader, S. Kang, and P. K. Vogt
Cancer-specific mutations in PIK3CA are oncogenic in vivo
PNAS, January 31, 2006; 103(5): 1475 - 1479.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Beloueche-Babari, L. E. Jackson, N. M.S. Al-Saffar, S. A. Eccles, F. I. Raynaud, P. Workman, M. O. Leach, and S. M. Ronen
Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells
Mol. Cancer Ther., January 1, 2006; 5(1): 187 - 196.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. J. Zhao, Z. Liu, L. Wang, E. Shin, M. F. Loda, and T. M. Roberts
The oncogenic properties of mutant p110{alpha} and p110{beta} phosphatidylinositol 3-kinases in human mammary epithelial cells
PNAS, December 20, 2005; 102(51): 18443 - 18448.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Oda, D. Stokoe, Y. Taketani, and F. McCormick
High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma
Cancer Res., December 1, 2005; 65(23): 10669 - 10673.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. J. Isakoff, J. A. Engelman, H. Y. Irie, J. Luo, S. M. Brachmann, R. V. Pearline, L. C. Cantley, and J. S. Brugge
Breast Cancer-Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells
Cancer Res., December 1, 2005; 65(23): 10992 - 11000.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Garcia-Rostan, A. M. Costa, I. Pereira-Castro, G. Salvatore, R. Hernandez, M. J.A. Hermsem, A. Herrero, A. Fusco, J. Cameselle-Teijeiro, and M. Santoro
Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer
Cancer Res., November 15, 2005; 65(22): 10199 - 10207.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. G. Campbell, S. E. Russell, W. A. Phillips, D. A. Levine, and J. Boyd
PIK3CA Mutations in Ovarian Cancer
Clin. Cancer Res., October 1, 2005; 11(19): 7042 - 7043.
[Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
T Frogne, J S Jepsen, S S Larsen, C K Fog, B L Brockdorff, and A E Lykkesfeldt
Antiestrogen-resistant human breast cancer cells require activated Protein Kinase B/Akt for growth
Endocr. Relat. Cancer, September 1, 2005; 12(3): 599 - 614.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Luo, C. L. Sobkiw, N. M. Logsdon, J. M. Watt, S. Signoretti, F. O'Connell, E. Shin, Y. Shim, L. Pao, B. G. Neel, et al.
Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase
PNAS, July 19, 2005; 102(29): 10238 - 10243.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Ikenoue, F. Kanai, Y. Hikiba, T. Obata, Y. Tanaka, J. Imamura, M. Ohta, A. Jazag, B. Guleng, K. Tateishi, et al.
Functional Analysis of PIK3CA Gene Mutations in Human Colorectal Cancer
Cancer Res., June 1, 2005; 65(11): 4562 - 4567.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. A. Levine, F. Bogomolniy, C. J. Yee, A. Lash, R. R. Barakat, P. I. Borgen, and J. Boyd
Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers
Clin. Cancer Res., April 15, 2005; 11(8): 2875 - 2878.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Baselga and C. L. Arteaga
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
J. Clin. Oncol., April 10, 2005; 23(11): 2445 - 2459.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. W. Cheng, J. P. Lahad, J. W. Gray, and G. B. Mills
Emerging Role of RAB GTPases in Cancer and Human Disease
Cancer Res., April 1, 2005; 65(7): 2516 - 2519.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. H. Saal, K. Holm, M. Maurer, L. Memeo, T. Su, X. Wang, J. S. Yu, P.-O. Malmstrom, M. Mansukhani, J. Enoksson, et al.
PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma
Cancer Res., April 1, 2005; 65(7): 2554 - 2559.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Shin, J. Edl, S. Biswas, P. C. Lin, R. Mernaugh, and C. L. Arteaga
Proapoptotic Activity of Cell-Permeable Anti-Akt Single-Chain Antibodies
Cancer Res., April 1, 2005; 65(7): 2815 - 2824.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
M. D. Pegram
Molecular Determinants of Trastuzumab Response/Resistance
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 155 - 159.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Campbell, I. G.
Right arrow Articles by Phillips, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Campbell, I. G.
Right arrow Articles by Phillips, W. A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online